<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00511160</url>
  </required_header>
  <id_info>
    <org_study_id>RBK103</org_study_id>
    <nct_id>NCT00511160</nct_id>
  </id_info>
  <brief_title>Cardiotropic Viruses in Cardiac Surgery Patients Without Clinical Evidence of Myocarditis or Myocarditic Sequelae</brief_title>
  <official_title>Prevalence of Cardiotropic Viruses in Cardiac Surgery Patients Without Clinical Evidence of Myocarditis or Myocarditic Sequelae</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Udo Sechtem</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Robert Bosch Gesellschaft für Medizinische Forschung mbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Myocarditis is mainly caused by cardiotropic viruses. In recent time viruses found in
      endomyocardial biopsies mainly consist of parvovirus B19 (PVB19) and human herpesvirus 6
      (HHV6). A definite causal link between virus-genome detection of PVB19 and/or HHV6 (via pcr
      techniques)and cardiac inflammation and dysfunction is however still missing.

      Primary objective:

      To determine the prevalence of PVB19 and HHV6 virus genome in heart muscle biopsies of
      cardiac surgery patients without clinical evidence of myocarditis or myocarditic sequelae

      Secondary objectives:

        1. Correlation of non-invasive myocarditis screening exams (cardiac magnetic resonance,
           ecg, history, inflammatory markers) with biopsy results

        2. Prognostic value of virus prevalence for the postoperative course

      Primary hypothesis:

      Patients without clinical evidence of myocarditis or myocarditic sequelae demonstrate to a
      significant lesser extent inflammatory activity and virus genome in their myocardium as
      compared to patients being clinical suspicious for myocarditis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective monocentric study with to 2 arms

      Study arm: Cardiac surgery group, Control arm: Routine cardiology group Minimum of 100
      patients included into the study arm

      Inclusion criteria for the study arm:

      Adult patients having cardiac surgery done under use of cardiopulmonary bypass

      Data collection:

      Past medical history, ecg, prior cardiovascular imaging (echo, ventriculography), cardiac
      magnetic resonance imaging (CMR), serologic studies, work-up of endomyocardial biopsies
      (histology, molecular-pathology, follow-up CMR.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study suspended due to logistical/personnel difficulties
  </why_stopped>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the prevalence of PVB19 and HHV6 virus genome in heart muscle biopsies of cardiac surgery patients without clinical evidence of myocarditis or myocarditic sequelae</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of non-invasive myocarditis screening exams (cardiac magnetic resonance, ecg, history, inflammatory markers) with biopsy results</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic value of virus prevalence for the postoperative course</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Myocarditis</condition>
  <arm_group>
    <arm_group_label>S</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study arm: Cardiac surgery group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Routine cardiology group</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Myocardial biopsies with TRU CUT 14 Gauge needle</intervention_name>
    <description>Myocardial needle biopsy and right atrial appendectomy</description>
    <arm_group_label>S</arm_group_label>
    <other_name>TRU CUT 14 Gauge needle</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endomyocardial biopsies</intervention_name>
    <description>The control arm C consists of routine-workup of patients with suspected myocarditis, independent of the study arm C, but with analogous screening methods and comparable biopsy sampling</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cardiac surgery with cardiopulmonary bypass

        Exclusion Criteria:

          -  No ability to give informed consent

          -  presence of so far accepted parvovirus/herpesvirus associated comorbidities

          -  contraindications for magnetic resonance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Udo P Sechtem, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Head of Cardiology, Robert Bosch Krankenhaus, Stuttgart, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulrich FW Franke, MD</last_name>
    <role>Study Director</role>
    <affiliation>Head of Cardiovascular Surgery, Robert Bosch Krankenhaus, Stuttgart, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Reinhardt Kandolf, MD</last_name>
    <role>Study Director</role>
    <affiliation>Director of Institute of Molecular Pathology University Tuebingen, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hannibal Baccouche, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, Robert Bosch Krankenhaus, Stuttgart, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hardy Baumbach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiovascular Surgery, Robert Bosch Krankenhaus Stuttgart, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robert Bosch Krankenhaus, Auerbachstrasse 110</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Wuerttemberg</state>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2007</study_first_submitted>
  <study_first_submitted_qc>August 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2007</study_first_posted>
  <last_update_submitted>October 4, 2016</last_update_submitted>
  <last_update_submitted_qc>October 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Robert Bosch Gesellschaft für Medizinische Forschung mbH</investigator_affiliation>
    <investigator_full_name>Udo Sechtem</investigator_full_name>
    <investigator_title>Prof. Udo Sechtem</investigator_title>
  </responsible_party>
  <keyword>myocarditis</keyword>
  <keyword>parvovirus B19 (PVB19)</keyword>
  <keyword>human herpes virus 6 (HHV6)</keyword>
  <keyword>cardiac magnetic resonance tomography (CMR)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocarditis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

